Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus
Exploratory Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus
Sponsor: Incyte Corporation
A PHASE2 clinical study on Discoid Lupus Erythematosus, this trial is completed. The trial is conducted by Incyte Corporation and has accumulated 10 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Enrolling By Invitation → Completed
-
Sep 2023 — Apr 2024 [monthly]
Enrolling By Invitation PHASE2
▶ Show 5 earlier versions
-
Jul 2023 — Sep 2023 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2022 — Jul 2023 [monthly]
Enrolling By Invitation PHASE2
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jan 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
- University of Rochester
For direct contact, visit the study record on ClinicalTrials.gov .